Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HCP1306 + RLD2302
- Development stage
- Unknown
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Small Molecules
01
Overview
**HCP1306 + RLD2302** is an experimental combination of two investigational agents evaluated for drug-drug interaction and safety in healthy volunteers in phase 1 clinical trials. The precise molecular identities of HCP1306 and RLD2302 are not published in accessible reference sources, but they are referenced as experimental compounds developed by Hanmi Pharmaceutical. The combination was studied for pharmacokinetics and safety; available evidence suggests their investigation is related to lipid disorders and hypertension, but direct mechanism and composition details are not publicly available[1][2][4][5].
- Other names
- HCP1306HCP-1306HCP 1306RLD2302RLD-2302RLD 2302
Beyond the preview
Go deeper on HCP1306 + RLD2302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HCP1306 + RLD2302.